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Abstract
Objectives To review the epidemiological and clinical fea-
tures of primary fallopian tube carcinoma (PFTC), and to il-
lustrate the spectrum of MRI findings, with pathological
confirmation.
Methods This article reviews the relevant literature on the
epidemiological, clinical, and imaging features of primary
fallopian tube carcinoma, with pathological confirmation,
using illustrations from the authors’ teaching files.
Results Primary fallopian tube carcinoma came under focus
over the last few years due to its possible role on the patho-
genesis of high-grade serous epithelial ovarian and peritoneal
cancers. Typical symptoms, together with the presence of
some of the most characteristic MRI signs, such as a
Bsausage-shaped^ pelvic mass, hydrosalpinx, and hydrometra,
may signal the presence of primary fallopian cancer, and allow
the radiologist to report it as a differential diagnosis.
Conclusions Primary fallopian tube carcinoma has a constel-
lation of clinical symptoms and magnetic resonance imaging
features, which may be diagnostic. Although these findings
are not present together in the majority of cases, radiologists
who are aware of them may include the diagnosis of primary
fallopian tube cancer in their report more frequently and with
more confidence.
Teaching Points
• PFTC may be more frequent than previously thought
• PFTC has specific clinical and MRI characteristics
•Knowledge of typical PFTC signs enables its inclusion in the
differential diagnosis
• PFTC is currently staged under the 2013 FIGO system
• PFTC is staged collectively with ovarian and peritoneal
neoplasms
Keywords Fallopian tube neoplasms .Magnetic resonance
imaging . High-grade serous carcinoma . Epithelial ovarian
cancer . Peritoneal cancer
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Introduction
Primary fallopian tube carcinoma (PFTC) has been described
as one of the rarest malignancies of the female genital tract,
accounting for around 1 % of all gynaecologic malignancies,
occurring predominantly in post-menopausal women at a
mean age of 55 years [1–7].
PFTC has come under focus in recent years, particularly in
pathology and oncology scientific literature, given the likely
role on the pathogenesis of ovarian cancer. This may have led
to underestimate the true incidence of PFTC as ovarian cancer
in the past, with significant clinical impact on the management
of these patients [1, 8–12]. Several papers have emerged
supporting the theory that high-grade serous ovarian carcino-
ma, as well as peritoneal carcinoma, may in fact originate
from occult high-grade serous carcinoma in the fallopian
tubes. The fimbriated ends of fallopian tubes could be the
dominant site of origin, particularly in high-risk BRCA muta-
tion carriers [7, 9, 11, 13–19].
PFTC is usually not suspected pre-operatively or even
intra-operatively due to its nonspecific clinical and surgical
presentation, particularly when disseminated [1, 3, 20–22].
Regarding imaging studies, PFTC is also rarely diagnosed in
pre-operative studies due to nonspecific findings and overlap
with ovarian cancer features [2, 3, 21–27].
The purpose of this study is to review the epidemiological
and clinical features of PFTC, and to illustrate the spectrum of
MRI findings, with pathological correlation.
Epidemiology
PFTC is considered a rare and aggressive type of tumour,
representing 0.14–1.8 % of the total gynaecological malignan-
cies [1, 5, 28]. The incidence of PFTC may be on the rise for
reasons that have not been completely understood. Associa-
tions between PFTC and socio-economic status and occupa-
tion have been described, with women of higher social classes
and education being at greater risk [5, 29].
Clinical presentation
The aetiology of this type of tumour has not been completely
explained. Hormonal, reproductive, and genetic factors may
play a role, along with the presence of chronic inflammation
of the pelvis [28].
PFTCmay have a constellation of characteristic symptoms,
namely colicky abdominal or pelvic pain and adnexal mass,
relieved by intermittent, profuse, serosanguineous vaginal dis-
charge, which constitute Laztko’s triad (seen in only 15 % of
patients). Hydrops tubae profluens is a syndrome character-
ized by the relief of pain and shrinkage of the abdominal or
pelvic mass by a vaginal discharge, which is caused by filling
and emptying of a sub-occluded fallopian tube (seen in only
5 % of patients). Typical symptoms, however, occur in only a
minority of patients with PFTC, and most women present with
less specific symptoms at the time of diagnosis [1, 28, 30–33].
The age of presentation is commonly between 40 and 60 years,
with a mean age of 55 years [28]. The pre-operative diagnosis
of PFTC is rarely performed, with clinical signs and symp-
toms pointing towards the more frequently occurring ovarian
cancer or pelvic inflammatory disease. Tumour markers, par-
ticularly CA-125, have no role in the diagnosis of PFTC.
Elevated CA-125 levels are, nevertheless, indicative of poor
prognosis, and can be used during follow-up, as a marker of
disease recurrence [34].
PFTC should be considered in the differential diagnosis
of patients with postmenopausal bleeding with negative
diagnostic curettage, cervical smear with intermittent sus-
picious abnormalities, and unexplained persistent vaginal
discharge [28, 30].
Pathological diagnosis
Pathology remains the mainstay for diagnosis of PFTC.
Serous carcinoma of the fallopian tube is the most common
histological type of tubal carcinoma. It is an invasive tu-
mour growing in papillary, glandular, and solid patterns
with high grade nuclear atypia. These tumours are identical
to their ovarian counterparts.
The second most common type of tumour is the
endometrioid carcinoma, followed by undifferentiated, clear
cell, mucinous, and transitional carcinomas [35].
PFTC is graded according to its differentiation and ex-
tent of solid components, with most tumours being poorly
differentiated [4, 36].
Initial diagnostic criteria for the diagnosis of PFTC were
proposed byHu et al. in 1950 [37]. These were revised later by
Sedlis et al. [38, 39] and currently include the following: 1.
The main tumour arises from the endosalpinx; 2. The histo-
logical pattern reproduces the epithelium of the tubal mucosa;
3. The transition from benign to malignant tubal epithelium is
demonstrable; 4. The ovaries or endometrium are either nor-
mal or contain a tumour that is smaller than the tumour in the
tube [28, 31]. Recently, Singh et al. [40], proposed an ap-
proach to the pathological assignment of primary site in
high-grade serous tubal, ovarian, and peritoneal carcinoma.
According to Singh, the identification of tumour inside the
fallopian tubes, even in the presence of larger tumours in other
localizations, supports the diagnosis of PFTC [40].
Dissemination of PFTC occurs through the transcoelomic
route with implantation of cells throughout the abdominal
cavity, similarly to ovarian cancer, and also through conti-
nuity to adjacent organs, transluminal migration,
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haematogenous, and lymphatic spread. Distant metastases
are more common in PFTC than ovarian cancer [28, 36,
41], but a biopsy of such lesions would not distinguish them
with certainty [41].
Staging
The currently accepted staging system for PFTC was devel-
oped by the International Federation of Gynecology and Ob-
stetrics (FIGO), and currently PFTC, ovarian, and peritoneal
cancers are staged collectively within the same system, al-
though occasionally it may be impossible to attribute the tu-
mour to a primary site [42]. Table 1 outlines the 2013 FIGO
staging classification for cancer of the ovary, fallopian tube,
and peritoneum.
Treatment
Current management of PFTC follows the same guidelines as
ovarian cancer in terms of surgical staging, debulking, and
adjuvant chemotherapy [43]. The main goal is to decrease
tumour load surgically. The surgical approach consists of total
abdominal hysterectomy, bilateral salpingo-oophorectomy,
and infra-colic omentectomy, appendicectomy, peritoneal
washings, and peritoneal biopsies [43, 44].
Routine pelvic and para-aortic lymphadenectomy is con-
sidered to be essential by some authors due to the strong
likelihood of lymphatic spread. However, this issue remains
controversial, and others believe that retroperitoneal node
sampling and dissection suffices [28, 45].
Postoperatively, chemotherapy plays an important role in
the management of early-stage PFTC, usually with platinum-
based combination chemotherapy. The efficacy of current che-
motherapy regimens has led to the abandonment of radiother-
apy as a treatment option for PFTC due to its poor results and
serious complications [1, 28].
Hormonal therapies may be of value in the future, given the
sensitivity and response of the fallopian tube epithelium to
hormonal fluctuations, although there are no current recom-
mendations [1, 28, 45].
Prognosis
The main prognostic factors identified for increased survival
include stage, age, and residual tumour after surgery, serous
subtype, and elevated pre-treatment CA-125 [28, 36]. The
presence of specific symptoms may lead to an earlier diagno-
sis and, consequently, improved survival.
Serous PFTC in advanced stage may have a better sur-
vival than its ovarian or peritoneal counterparts [43, 46].
Earlier stage PFTC disease could also have better survival
rates, given the possibility of presenting earlier and the
established role of lymphadenectomy in its management.
Other authors have suggested that survival outcomes are
similar between PFTC and ovarian cancer, in support of
identical therapeutic approaches for both types of tumours
[47], and some report better survival in ovarian cancer pa-
tients compared to equivalent stage patients with PFTC.
The 5-year survival rate of PFTC ranges between 22 and
57 % [28].
Recurrent disease, which occurs on average 2 to 3 years
after initial treatment, is associated with a dismal prognosis
due to the lack of alternative treatments available [28].
Imaging PFTC
Imaging diagnosis of PFTC is important because it can
help planning adequate initial surgery and avoid second-
look laparotomy. Imaging findings of PFTC are usually
nonspecific, and a tubo-ovarian abscess or ovarian tumour
may appear to be the most likely diagnosis given their
higher prevalence [26].
Similarly to other gynaecologic tumours, the imaging ap-
proach includes ultrasound as the initial modality, followed by
MRI for undetermined or suspicious adnexal masses and com-
puted tomography (CT) or MRI for complete staging. CT is
only used for staging purposes and not for pelvic mass char-
acterization due to low soft-tissue contrast in comparison to
MRI [2, 48].
On greyscale ultrasound, PFTC may be suspected in the
presence of a tubular-shaped mass (or sausage-shaped) or a
lobular mass with a cogwheel pattern [49]. On Doppler ultra-
sound, a low-impedance flow within the solid components
may be a clue [50]. Variability of imaging characteristics in
serial imaging may also point towards PFTC [51].
MRI is the modality of choice for evaluating an undeter-
mined pelvic mass on ultrasound and also to evaluate the
local burden of tumour [52, 53]. Recently Ma et al. [48]
have outlined the use of MRI for differentiating PFTC from
epithelial ovarian cancer (EOC). According to their assess-
ment of MRI features, the characteristic appearance of PFTC
was a relatively small, tubular-shaped (or sausage-shaped)
mass, with homogenous signal, low signal intensity on T1
weighted images (T1WI), high signal intensity on T2
weighted images (T2WI), mild to moderate enhancement,
and hydrosalpinx or intrauterine fluid. Ma et al. identified
tubular (sausage) shape, hydrosalpinx, and the presence of
intra-uterine fluid as the most specific direct and indirect
signs of PFTC. The combination of an adnexal mass with
at least one of the former features yields a high diagnostic
accuracy [48].
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Anatomy of the fallopian tubes on MRI
The normal fallopian tubes are usually not visualized on
pelvic MRI. In the presence of intraperitoneal fluid, they
may be seen as paired thin structures, extending from the
ovaries to the uterine cornua, in the superior edge of the
broad ligament [2]. They extend for about 10–12 cm al-
though they will appear shorter due to being convoluted
on cross-sectional imaging. The fallopian tubes are divided
into four portions, the intramural/interstitial on the medial
end, the isthmus, the ampulla, and the infundibulum at the
lateral fimbriated end [26] (Fig. 1).
Table 1 2013 FIGO staging classification for cancer of the ovary, fallopian tube, and peritoneum
Primary tumor (T)
TNM FIGO Description
Tx – Primary tumor cannot be assessed
T0 – No evidence of primary tumor
T1 I Tumor confined to the ovaries or fallopian tubes
T1a IA Tumor limited to one ovary (capsule intact) or fallopian tube; no tumor on ovarian or fallopian tube surface;
no malignant cells in ascites or peritoneal washings
T1b IB Tumor limited to both ovaries (capsule intact) or fallopian tubes; no tumor on ovarian or fallopian tube surface;
no malignant cells in ascites or peritoneal washing
T1c IC Tumor limited to one or both ovaries or fallopian tubes with any of the following:
IC1 - Surgical spill
IC2 - Capsule ruptured before surgery or tumor on ovarian or fallopian tube surface
IC3 - Malignant cells in the ascites or peritoneal washings
T2 II Tumor involves one or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or peritoneal cancer
T2a IIA Extension and/or implants on uterus and/or tube(s) and/or ovaries
T2b IIB Extension to other pelvic intraperitoneal tissues
T3 III Tumor involves one or both ovaries or fallopian tubes, or peritoneal cancer, with cytologically or histologically
confirmed spread to the peritoneum outside the pelvis and/or metastases to the retroperitoneal lymph nodes
T3a IIIA Positive retroperitoneal lymph nodes and/or microscopic metastasis beyond pelvis
IIIA1 Positive retroperitoneal lymph nodes only (cytologically or histologically proven)
IIIA1 (i) Metastasis up to 10 mm in greatest dimension
IIIA1 (ii) Metastasis more than 10 mm in greatest dimension
IIIA2 Microscopic extrapelvic (above the pelvic brim) peritoneal involvement, with or without positive retroperitoneal lymph nodes
T3b IIIB Macroscopic peritoneal metastasis beyond pelvis up to 2 cm in greatest dimension, with or without metastasis
to the retroperitoneal lymph nodes
T3c IIIC Macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension, with or without metastasis
to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal
involvement of either organ)
IV Distant metastasis excluding peritoneal metastases
IVA Pleural effusion with positive cytology
IVB Parenchymal metastases and metastases to extra-abdominal organs (including inguinal lymph nodes and lymph
nodes outside the abdominal cavity)
Regional lymph nodes (N)
Nx – Regional lymph nodes cannot be assessed
N0 – No regional lymph node metastases
N1 III Regional lymph node metastases
Distant metastasis (M)
M0 – No distant metastases
M1 IV Distant metastasis (excludes peritoneal metastases)
IVA Pleural effusion with positive cytology
IVB Parenchymal metastasis and metastases to extra-abdominal organs (including inguinal lymph nodes and lymph
nodes outside the abdominal cavity)#
Adapted from Prat J (2014) Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum. Int J Gynaecol Obstet 124:1–5 (reference
42). (*) Dense adhesions with histologically proven tumour cells justify upgrading to stage II. (#) Transmural bowel infiltration or umbilical deposit are
stage IVB
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Fig. 1 Thirty-two-year-old female imaged for other purposes. T2WI
coronal oblique section through the pelvis showing a normal uterus,
both ovaries, and the full length of the left fallopian tube. On the right
hand side of the image, an illustration of the fallopian tube anatomy can
be observed, based on the MR image see on the left, showing the four
segments of the tube: intramural, isthmus, ampulla, and fimbriae
Fig. 2 Serous PFTC in a 63-year-
old female, presenting with pelvic
pain. a Axial T2WI through the
pelvis, showing Bsausage^-
shaped mass (asterisk).
Incomplete folds (red arrow) and
the Bwaist^ sign (white arrows),
are in favour of a fallopian tube
mass; b Sagittal T2WI with the
same solid mass (asterisk), inside
a structure with well-defined
walls (white arrowhead), the
Bwaist^ sign (white arrows),
incomplete folds (red arrow), and
the Bsynechiae^ sign (red
arrowhead) with strands of tissue
floating in the fluid-filled
fallopian tube; c Coronal T2WI,
with the Bsausage^-shaped mass
(asterisk) folded upon itself, as
depicted by the portions of wall
visible inside the mass (red
arrow), which approximates the
Bspoke-wheel^ sign, usually
better depicted when the mass is
predominantly cystic. Once again,
the Bsynechiae^ sign can be
observed (red arrowhead); d
T1WI, fat-saturated, post-contrast
image, showing the enhancement
of the solid portions of the mass.
Courtesy of Dra. Rosana Santos
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Tubular/sausage-shaped mass
The tubular nature of these paired organs is seen behind the
sausage-shaped appearance when they are filled with solid
tumour (Fig. 2). This is one of the most specific signs seen
in PFTC, particularly in the presence of contrast enhancement
of the mass (Figs. 2d and 5d). The solid tumour may have
variable T1 hypointensity and T2 hyperintensity and show a
high signal in diffusion weighted imaging (DWI) (Fig. 5).
Other pathologies can present with hydrosalpinx and solid
component, such as a tubo-ovarian abscess, and differentia-
tion from malignancy can be challenging.
Hydrosalpinx
Hydrosalpinx forms in PFTC both due to the copious
amounts of fluid produced by the tumour and to the partial
obstruction of the tubes. This leads to tubular distention and
can be easily observed in T2WI sequences. Frequently, one
of the ends of the tube is patent, leading to decompression of
the tubal obstruction with discharge and consequent shrink-
age of the pelvic mass, resulting in a temporary resolution of
symptoms, as described in the clinical presentation. This
variability of size and shape of the mass can be seen in serial
imaging. MRI can easily detect the presence of
hydrosalpinx, which usually appears as a cystic, tubular-
shaped, convoluted mass, with well-defined walls. The di-
lated tubes contain incomplete plicae or folds, producing its
convoluted appearance, either seen as the Bwaist sign^
(Fig. 2), causing focal constriction of the tubular structure,
or as the Bbeak sign^ (Figs. 3a and 4a), reflecting an acute
angular contour, which would not be seen on a regular tu-
bular or round structure [25]. This is distinct from the Bbeak
sign^ described as an indicative feature of an intra-ovarian
lesion [54]. When a fallopian tube is extremely dilated by
fluid, it may fold upon itself to produce the Bcogwheel
sign^, which may be indistinguishable from an ovarian
Fig. 3 Serous PFTC in a 78-year-
old female, presenting with
postmenopausal bleeding and
pelvic pain. a Sagittal T2WI
showing a solid mass (asterisk)
with well-defined walls (white
arrow), incomplete folds (red
arrow), and an incidental cystic
lesion corresponding to a
cystadenofibroma (blue
arrowhead); b Axial T2WI
showing the ovarian
cystadenofibroma, posterior to the
mass (blue arrowhead); c Axial
DWI with the same solid mass
showing restriction to diffusion; d
Axial T1WI, fat-saturated,
contrast-enhanced image,
showing contrast uptake by the
mass, with central necrosis
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neoplasm [2]. Occasionally, the Bsynechiae sign^, consisting
of fine strands running across the lumen, can also be seen in
dilated fallopian tubes [25] (Fig. 2b). Another MRI sign asso-
ciated with the fallopian tubes is the Bamorphous shading
sign^, corresponding to the loss of signal intensity of the fluid
filled tubes from T1WI to T2WI. The high viscosity and the
presence of protein and iron due to recurrent haemorrhage,
similar to what is seen in ovarian lesions, can explain this
phenomenon [55]. The patency of the fallopian tube can lead
to discharge of fluid into either the intra-uterine or the perito-
neal cavities. However, ascites is not a specific sign of PFTC
and is frequently present in ovarian cancer. Intra-uterine fluid,
on the other hand, is specific of PFTC and it can occur in up to
30 % of cases [48] (Figs. 4b and 5).
Conclusions
PFTC can be suspected on MRI when specific fallopian-tube
related signs are present. However, the likelihood to present
when already spread to the ovaries or peritoneum makes this
diagnosis challenging, even for the experienced radiologist.
PFTC has a variety of MRI findings, which make it diffi-
cult to suspect its origin based solely on imaging. However,
radiologists can be more suspicious in the presence of features
related to fallopian tube disease, such as a relatively small,
tubular-shaped (or sausage-shaped) mass, with homogenous
signal, low signal intensity on T1WI, high signal intensity on
T2WI, with mild to moderate enhancement, and associated
hydrosalpinx or intrauterine fluid.
Fig. 5 Serous PFTC in a 64-year-old female, presenting with abdominal
pain. a Sagittal T2WI showing a Bsausage^-shaped solid mass, folded
upon itself as shown by the portion of Fallopian tube wall on the centre of
the mass (arrowhead), and again the Bbeak^ sign is depicted (dashed
arrow); b Sagittal T2WI where the mass can still be seen (asterisk),
together with an important sign in PFTC: hydrometra (red dashed arrow)
Fig. 4 Serous PFTC in a 58-year-old female, presenting with postmen-
opausal bleeding. a Axial T2WI showing a left hydrosalpinx with well-
defined walls (arrowhead), mural nodules (asterisk), the Bbeak sign^
(dashed arrow), and an enlarged left obturator lymph node (blue arrow);
b Coronal T2WI showing the same mural nodules (asterisk) inside the
fluid-distended left fallopian tube, in transverse section
Insights Imaging (2015) 6:431–439 437
Singh’s [40] proposal for the histopathological diagnosis of
high grade serous carcinoma, suggests assigning the fallopian
tube as the primary site whenever there is a fallopian tube
mass, even in the presence of other larger concomitant tu-
mours. Radiologists should feel more confident in suspecting
PFTC, and reporting it on their differential, in the presence of
an adnexal mass associated to one or more of the three more
specific signs (tubular-shaped mass, hydrosalpinx, and intra-
uterine fluid accumulation), particularly in earlier stage dis-
ease and when the ovaries can be identified as normal.
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